NSRX Ipo

Nasus Pharma Announces Closing of Initial Public Offering

Published August 14, 2025 at 08:05 PM

TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the closing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share. The gross proceeds of the offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Nasus Pharma’s shares began trading on the NYSE American LLC exchange on August 13, 2025 under the ticker symbol “NSRX”. Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, to purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions.

Related Questions

What is the expected use of the $10 million net proceeds from the IPO? What is the current demand and order book for the IPO—were there oversubscriptions or a strong investor appetite? What are the key milestones in Nasus Pharma’s clinical pipeline that could drive stock momentum in the near term? How might the company’s regulatory timeline (e.g., FDA submissions) influence price volatility after the debut? Are there any strategic partnerships or licensing agreements in place that could affect the company’s growth trajectory? How will the underwriters' 45‑day option to purchase additional shares affect future dilution and share supply? What is the anticipated lock‑up period for existing shareholders and how might that impact post‑IPO trading dynamics? How does the $8.00 IPO price compare to valuations of similar intranasal‑therapy companies and recent IPOs in the sector? What is the expected float percentage and daily trading volume, and how could that affect liquidity and price stability? What are the potential short‑term and long‑term risks (e.g., competition, reimbursement, market adoption) that could impact the stock’s performance?